Status:

COMPLETED

JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population

Lead Sponsor:

Allergan

Conditions:

Temple Hollowing

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The objectives of this study are to evaluate the safety and effectiveness of JUVÉDERM® VOLUMA® with Lidocaine injectable gel in adult Chinese population seeking correction of temple hollowing.

Eligibility Criteria

Inclusion

  • Participant must be 18 or over, at the time of signing the ICF
  • Participants seeking improvement of temple hollowing
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
  • Written informed consent from the participant has been obtained prior to any study-related procedures
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
  • Is able to complete effectiveness self-assessments without the use of glasses (contact lens use is acceptable if they will be used for all participant self-assessments)

Exclusion

  • Temple hollowing due to trauma, congenital malformations, or lipodystrophy, either congenital or acquired
  • Has experienced trauma to the temple area within 6 months before enrollment or has residual deficiencies, deformities, or scarring
  • Temporal arteritis or history of temporal arteritis
  • Temporomandibular joint dysfunction or any other jaw issues
  • Recurrent temporal headaches such as temporal tendinitis migraine
  • Active or recurrent inflammation or infection in either eye
  • Tendency to develop hypertrophic scarring
  • Active autoimmune disease
  • History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein
  • Current cutaneous or mucosal inflammatory or infectious processes (e.g. acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion, above the subnasal
  • Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)
  • Fat injection or permanent facial implants anywhere in the face
  • Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment
  • Temporary dermal filler injections above the subnasale within 12 months before enrollment
  • Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment (examples of mesotherapy or cosmetic facial procedures are laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures.
  • Injections in the nasolabial fold are acceptable only if done at least 3 months prior to enrollment
  • Botulinum toxin treatment above the subnasale within 6 months before enrollment
  • Has braces or other orthodontics
  • Not eligible for this study if participants have begun using any new over the counter or prescription oral or tropical, anti-wrinkle products above the subnasale within 30 days before enrollment. Participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study
  • Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)
  • Has tattoos, piercings, facial hair, or scars above and including the subnasale that would interfere with visual assessment of the temple
  • Females who are pregnant, nursing, or planning a pregnancy
  • Plans a significant weight change (more than 10% of body weight) during the study

Key Trial Info

Start Date :

July 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 22 2023

Estimated Enrollment :

168 Patients enrolled

Trial Details

Trial ID

NCT04891419

Start Date

July 20 2021

End Date

November 22 2023

Last Update

December 12 2024

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

China-Japan Friendship Hospital /ID# 241680

Beijing, Beijing Municipality, China, 100029

2

Beijing Hospital /ID# 233582

Beijing, Beijing Municipality, China, 100730

3

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233602

Wuhan, Hubei, China, 430022

4

Nanjing Drum Tower Hospital /ID# 233607

Nanjing, Jiangsu, China, 210008

JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population | DecenTrialz